Activation of the protective arm of renin-angiotensin system enhances mitochondrial turnover improving respiration and decreasing integrated stress response in a human Complex III deficiency model.

The study demonstrates that CAP-1902, a novel MasR agonist, acts as a mitophagy inducer that enhances mitochondrial turnover by activating the AMPK/ULK1/FUNDC1 pathway and stimulating biogenesis, thereby rescuing bioenergetic defects and reducing the integrated stress response in human fibroblasts with Complex III deficiency.

The Gist

The Big Picture: Fixing a Broken Power Plant

Imagine your body's cells are like bustling cities, and inside every city, there are thousands of tiny power plants called mitochondria. These power plants generate the electricity (energy) your cells need to run, think, and move.

In people with mitochondrial diseases, these power plants are broken. They are old, rusty, and can't make enough electricity. Worse, the city's "cleanup crew" (the cell's natural recycling system) is overwhelmed. It can't get rid of the broken power plants fast enough, and it can't build new, healthy ones quickly enough. The result? The city runs on fumes, and the trash piles up, causing stress and damage.

This paper introduces a new "magic key" called CAP-1902 that helps the city fix itself.

---

The Problem: A Clogged Recycling Bin

In a healthy cell, there is a perfect balance:

1. Recycling (Mitophagy): The cell finds broken mitochondria, wraps them up, and throws them in the trash (lysosome) to be destroyed.
2. Construction (Biogenesis): The cell builds brand new, shiny mitochondria to replace the old ones.

In patients with Complex III deficiency (a specific type of mitochondrial disease), the recycling crew is confused. They aren't throwing away the broken power plants fast enough, and the construction crew isn't building new ones efficiently. The cell is stuck with a mix of broken and working plants, leading to a power outage and a lot of stress.

The Solution: The "Protective Arm" of the System

The researchers discovered that the cell has a built-in control system called the Renin-Angiotensin System (RAS). Think of this system like a thermostat with two settings:

• The "Red Light" Setting: This causes stress and inflammation (bad for mitochondria).
• The "Green Light" Setting (The Protective Arm): This promotes health and repair.

The researchers found a new drug, CAP-1902, that acts like a remote control to switch the system to the "Green Light." It specifically targets a receptor on the cell surface called MasR (the "Green Light" button).

How the Drug Works: The Three-Step Rescue Plan

When CAP-1902 hits the "Green Light" button, it triggers a chain reaction that fixes the cell in three clever ways:

1. The "Garbage Truck" Gets a Boost (Mitophagy)

The drug wakes up a supervisor protein called AMPK. Think of AMPK as the city manager who realizes, "Hey, we have too much trash!"

• The manager tells a worker named ULK1 to get to work.
• ULK1 then activates a specialized garbage collector named FUNDC1.
• The Magic: FUNDC1 is smart. It doesn't just grab any mitochondria; it specifically hunts down the broken, depolarized ones (the ones that lost their power). It wraps them up and sends them to the trash can.
• Analogy: It's like a smart trash robot that only picks up broken toasters and leaves the working ones alone.

2. The "Construction Crew" Gets a Boost (Biogenesis)

While the garbage truck is taking out the trash, the drug also tells the construction crew to build new power plants.

• It activates a foreman named PGC-1α, who runs to the cell's "headquarters" (the nucleus).
• PGC-1α flips the switches to start building new, efficient mitochondria.
• Analogy: As soon as the old, rusty toasters are hauled away, a factory immediately starts manufacturing brand-new, high-efficiency toasters.

3. The Balance is Restored

The best part is that the drug does both at the same time.

• If you only remove the trash without building new plants, the city runs out of power.
• If you only build new plants without removing the trash, the city gets clogged with junk.
• CAP-1902 ensures that for every broken plant removed, a new one is built. The total number of power plants stays the same, but the quality of the population improves dramatically.

The Results: A Healthier City

When the researchers tested this on cells from patients with the disease, they saw amazing results:

• Less Stress: The "stress alarms" in the cell (which usually scream when things are broken) turned off.
• Better Power: The cells started producing energy much more efficiently.
• Cleaner Streets: The broken power plants disappeared, and the "trash cans" (lysosomes) were in the right place to do their job.

Why This Matters

Currently, there are very few treatments for mitochondrial diseases. Most treatments try to fix one specific broken part, but because every patient's disease is slightly different, a "one-size-fits-all" cure is hard to find.

This study suggests a new strategy: Instead of trying to fix the specific broken gear, why not just upgrade the whole system's ability to recycle and rebuild?

By using CAP-1902 to turn on the "Green Light," the cell can clean out its own mess and build its own solutions. This could be a game-changer for treating not just this specific disease, but many others where mitochondria are failing. It's like giving the city a self-cleaning, self-repairing upgrade that works for almost any type of power plant failure.

Technical Summary

Title

Activation of the protective arm of the renin-angiotensin system enhances mitochondrial turnover, improving respiration and decreasing the integrated stress response in a human Complex III deficiency model.

1. The Problem

Primary mitochondrial diseases (PMDs) are genetically heterogeneous disorders caused by defects in the oxidative phosphorylation (OXPHOS) system. A shared hallmark of these diseases is the accumulation of dysfunctional mitochondria. Current therapeutic strategies face significant challenges:

• Simply promoting mitophagy (degradation of damaged mitochondria) without correcting the specific dysfunction can exacerbate clearance impairment.
• Enhancing degradation without simultaneously stimulating mitochondrial biogenesis can lead to a net depletion of mitochondria, worsening cellular bioenergetics.
• There is a critical need for therapies that induce balanced mitochondrial turnover (simultaneous removal of damaged organelles and generation of new, functional ones) to restore homeostasis in OXPHOS-deficient conditions.

2. Methodology

The study utilized a human cellular model of Complex III (CIII) deficiency derived from patient fibroblasts carrying BCS1L mutations (P1: BCS1L^R73C/F368I and P2: BCS1L^R183C/R184C).

• Compound: The researchers investigated CAP-1902, a novel, potent, and selective small-molecule agonist of the Mas Receptor (MasR), a component of the protective arm of the Renin-Angiotensin System (RAS).
• Cell Models:
  • Patient-derived CIII-deficient fibroblasts.
  • Control fibroblasts.
  • Cells stably expressing the mito-QC reporter (GFP-mCherry) to visualize mitophagy flux.
  • Cells with FUNDC1 knockdown (KD) via shRNA to validate pathway specificity.
• Key Techniques:
  • High-content and Confocal Microscopy: To assess mitochondrial mass (GRP75, TOMM20, mtDNA staining), morphology, membrane potential (TMRE/MTG), and lysosomal distribution (LAMP1).
  • Mito-QC Assay: To quantify mitophagy flux (red puncta representing mitolysosomes) in the presence and absence of lysosomal inhibitors (Leupeptin/Pepstatin A).
  • Respirometry (Seahorse XF): To measure Oxygen Consumption Rate (OCR), Extracellular Acidification Rate (ECAR), and ATP production in glucose and galactose media.
  • Molecular Biology: RNA-seq for transcriptomic analysis, Western blotting for protein levels (OXPHOS complexes, AMPK, ULK1, FUNDC1, PGC1α, ATF4, CHOP), and subcellular fractionation (nuclear/cytoplasmic/mitochondrial).
  • STED Microscopy: To visualize cristae structure in live cells.

3. Key Contributions

• Novel Mechanism: This is the first study to link MasR activation directly to the regulation of mitochondrial turnover via the AMPK/ULK1/FUNDC1 axis in the context of mitochondrial disease.
• Balanced Turnover: Demonstrates that MasR activation induces a balanced cycle of mitophagy and biogenesis, avoiding the pitfalls of net mitochondrial loss or accumulation.
• Selective Targeting: Shows that CAP-1902 selectively targets already depolarized mitochondria for degradation without inducing further depolarization.
• Therapeutic Candidate: Identifies CAP-1902 as a potential first-in-class GPCR-mediated treatment for mitochondrial diseases.

4. Key Results

A. Induction of Mitochondrial Turnover

• Mitophagy Flux: CAP-1902 treatment significantly increased mitophagy flux (mitolysosome formation) in CIII-deficient cells.
• Selectivity: The treatment did not cause global mitochondrial depolarization. Instead, it selectively reduced the number of small, depolarized mitochondria, indicating the clearance of damaged organelles.
• Pathway Specificity:
  • CAP-1902 activated AMPK (p-AMPK T172) within 10–30 minutes.
  • This led to the phosphorylation of ULK1 (S638) and subsequently FUNDC1 (S17).
  • FUNDC1 KD blocked the CAP-1902-induced increase in mitophagy flux, confirming FUNDC1 is essential for this process.
  • Crucially, FUNDC1 KD did not block AMPK activation or PGC1α nuclear translocation, proving the pathway branches downstream of AMPK.

B. Restoration of Mitochondrial Biogenesis

• PGC1α Activation: CAP-1902 restored the nuclear translocation of PGC1α, which was impaired in CIII-deficient cells.
• Transcriptional Changes: RNA-seq revealed upregulation of genes related to respiratory electron transport, mitochondrial translation, and biogenesis (e.g., PPRC1).
• Protein Levels: Treatment increased the levels of ETC components (CI, CII, CIV, CV) and PROHIBITIN (a marker of cristae integrity), suggesting an increase in OXPHOS capacity per cristae rather than just an increase in total mitochondrial mass.
• Balance: Despite increased biogenesis and mitophagy, total mitochondrial mass remained stable, indicating a successful turnover cycle.

C. Functional Rescue and Stress Reduction

• Bioenergetics: CAP-1902 rescued maximal respiration, ATP-linked respiration, and reserve capacity in CIII-deficient cells. It also reduced proton leak, indicating improved efficiency.
• Integrated Stress Response (ISR): CIII deficiency caused elevated nuclear levels of ATF4 and CHOP (markers of ER stress and apoptosis). CAP-1902 treatment significantly reduced these markers, indicating a return to cellular homeostasis.
• Lysosomal Distribution: CIII-deficient cells exhibited aberrant peripheral lysosomal distribution (inhibiting autophagy). CAP-1902 restored the perinuclear clustering of lysosomes, facilitating autophagic flux, without altering lysosomal numbers or enzymatic activity.

5. Significance

• Therapeutic Strategy: The study proposes that inducing balanced mitochondrial turnover is a viable, shared therapeutic strategy for diverse mitochondrial diseases, regardless of the specific genetic mutation.
• RAS as a Target: It establishes the protective arm of the Renin-Angiotensin System (MasR) as a critical regulator of mitochondrial quality control. This opens a new avenue for drug development using MasR agonists (like CAP-1902 or the clinical candidate BIO101/Sarconeos).
• Mechanistic Insight: The elucidation of the MasR $\rightarrow$ AMPK $\rightarrow$ ULK1/FUNDC1 $\rightarrow$ Mitophagy and AMPK $\rightarrow$ PGC1$\alpha$ $\rightarrow$ Biogenesis pathways provides a clear molecular blueprint for how to pharmacologically restore mitochondrial health.
• Clinical Relevance: By correcting bioenergetic defects and reducing cellular stress (ISR) without depleting mitochondrial mass, CAP-1902 represents a promising candidate for treating primary mitochondrial disorders, potentially overcoming the limitations of current mitophagy inducers that may cause excessive mitochondrial loss.